Waves of pharmaceutical product innovation require environmental monitoring approaches that can advance in lockstep with the increasing range of emerging modalities and advanced therapies.
Amid this progress, traditional environmental monitoring practices remain the standard for detection of environmental signals. Despite a focus on rapid microbiological methods, the uptake and acceptance of alternative methods has been slower than expected.
This session will discuss:
- Why traditional EM methods remain the standard and expectation as other technologies advance at greater pace
- Validating approaches for alternative methods
- Assessing advanced EM methods and how they can be leveraged for advanced compliance
- Becoming more proactive in environmental monitoring
